- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01841931
Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients
23. marts 2018 opdateret af: Maimonides Medical Center
Buprenorphine Tx:A Safe Alternative for Opioid Dependent Pain Patients
The purpose of this study is to examine whether buprenorphine can be at least as effective as other opioid medications in relieving chronic pain in patients who suffer from dependence on their opioid medications, while patients simultaneously experience progressive decline of pain along with absence of opioid withdrawal symptoms and improved quality of life.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study will utilize sublingual buprenorphine for the treatment of chronic pain patients with co-occurring opioid dependence.
Adult male and female chronic pain patients with co-occurring opioid dependence/disorder, being treated at MMC will be enrolled in a home induction procedure.
Subjects will be switched from their current opioid pain medication to buprenorphine/naloxone to assess whether buprenorphine is at least as effective, if not more effective, as other opioid medications in controlling their pain while simultaneously improving their psychological distress, functional status, and other aspects of patients' lives.
We will utilize a home induction procedure, and maintain subjects on this oral medication for a duration of 6 months.
During this period
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
4
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11219
- Maimonides Medical Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Meets DSM criteria for opioid dependence (or opioid use disorder when DSM 5 is in use)
- Has received opioid therapy for at least 90 days
- Has opioid dependence as assessed by a Maimonides psychiatrist
Exclusion Criteria:
- Scheduled for major surgery during study duration
- Predicted life expectancy < 1 year
- Plan to cease habitation in greater New York area within 6 months
- Risks for buprenorphine outweigh potential benefit, as determined by the PI
- Lacks sufficient fluency in English to understand the study protocol, answer survey questions or give informed consent
- Pregnant women
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Opiate Withdrawal
Tidsramme: 6 months
|
Goal that patients will have NO withdrawal symptoms by the completion of their 3-day buprenorphine induction, and will remain withdrawal-free for the entire study duration.Assessed using Clinical Opiate Withdrawal Scale (COWS).
|
6 months
|
Pain Severity
Tidsramme: 6 months
|
Pain severity will be measured using a numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine), adopted from the Brief Pain Inventory (BPI). No results to report. |
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Psychiatric Distress
Tidsramme: 6 months
|
The investigators will utilize the SCL-6 (Symptoms Checklist 6, a validated abbreviated version of the SCL-90) to assess patients' psychological well being.
|
6 months
|
Quality of Life
Tidsramme: 6 months
|
Investigators will use the QOL (EuroQol EQ5D) questionnaire, which assess patients' self-assessment of health and health-related quality of life.
|
6 months
|
Positive Affect
Tidsramme: 6 months
|
The investigators will assess patients' moods/affects using the PANAS (Positive Affect Negative Affect Scale).
|
6 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Andrew Kolodny, MD, Maimonides Medical Center Dept. of Psychiatry Chairman
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.
- EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9.
- TEDS. Treatment Episode Data Set, 1998-2008. Subsance Abuse and Mental Health Services Administration, Office of Applied Studies, http://wwwdasis.samhsa.gov/webt/NewMapv1.htm
- Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994 May;55(5):569-80. doi: 10.1038/clpt.1994.71.
- Rosen CS, Drescher KD, Moos RH, Finney JW, Murphy RT, Gusman F. Six- and ten-item indexes of psychological distress based on the Symptom Checklist-90. Assessment. 2000 Jun;7(2):103-11. doi: 10.1177/107319110000700201.
- Sobell, L.C., & Sobell, M.B., Alcohol Timeline Followback (TFLB), in Handbook or Psychiatric Measures, I.A.P.A. (ed.), Editor. 2000, American Psychiatric Association: Washington, D.C. p. 477-479.
- Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009 Feb;24(2):226-32. doi: 10.1007/s11606-008-0866-8. Epub 2008 Dec 17.
- Schilthuizen M, Stouthamer R. Horizontal transmission of parthenogenesis-inducing microbes in Trichogramma wasps. Proc Biol Sci. 1997 Mar 22;264(1380):361-6. doi: 10.1098/rspb.1997.0052.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. februar 2013
Primær færdiggørelse (Faktiske)
1. juli 2013
Studieafslutning (Faktiske)
1. august 2013
Datoer for studieregistrering
Først indsendt
25. januar 2013
Først indsendt, der opfyldte QC-kriterier
26. april 2013
Først opslået (Skøn)
29. april 2013
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
23. april 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. marts 2018
Sidst verificeret
1. juli 2013
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Kemisk inducerede lidelser
- Stof-relaterede lidelser
- Narkotika-relaterede lidelser
- Opioid-relaterede lidelser
- Lægemidlers fysiologiske virkninger
- Depressive midler til centralnervesystemet
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Analgetika, Opioid
- Narkotika
- Narkotiske antagonister
- Buprenorphin
- Naloxon
- Buprenorphin, Naloxon-lægemiddelkombination
Andre undersøgelses-id-numre
- 11/09/VA05
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Opioidbrugsforstyrrelse
-
University of MichiganThe Benter FoundationAktiv, ikke rekrutterendeOpioid ordinationForenede Stater
-
matthieu clanetAfsluttet
-
University of MichiganNational Institute on Drug Abuse (NIDA)AfsluttetOpioid ordinationForenede Stater
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesAfsluttetAnalgetika OpioidForenede Stater
-
Purdue Pharma LPAfsluttetOpioid analgesiForenede Stater, Australien, Finland, New Zealand
-
Second Hospital of Shanxi Medical UniversityRekrutteringOpioid analgetisk bivirkningKina
-
St. Louis UniversityAfsluttetOpioid-vedligeholdte gravide kvinder
-
Frederiksberg University HospitalAfsluttet
-
Centre Hospitalier Universitaire DijonAfsluttetOpioidfri anæstesi | Opioid anæstesiFrankrig
-
Centre Hospitalier Universitaire DijonAfsluttetOpioidfri anæstesi | Opioid anæstesiFrankrig
Kliniske forsøg med Buprenorphine/Naloxone
-
Duke UniversityNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCAfsluttetOpioidbrugsforstyrrelseForenede Stater
-
Montefiore Medical CenterRekruttering
-
Yale UniversityNational Institute on Drug Abuse (NIDA)AfsluttetOpiatafhængighedForenede Stater
-
CBT4CBT, LLCAfsluttet
-
Indivior Inc.Afsluttet
-
National Institute on Drug Abuse (NIDA)Cincinnati MDRUAfsluttetStof-relaterede lidelser | Opioid-relaterede lidelserForenede Stater
-
National Institute on Drug Abuse (NIDA)AfsluttetOpioid-relaterede lidelserForenede Stater
-
National Institute on Drug Abuse (NIDA)New York MDRUAfsluttetOpioid-relaterede lidelser | HeroinafhængighedForenede Stater
-
University of PennsylvaniaPublic Health Management Corporation; Philadelphia Department of Public... og andre samarbejdspartnereAfsluttetOverdosis | OpioidbrugsforstyrrelseForenede Stater
-
Bicycle HealthTilmelding efter invitationOpioidbrugsforstyrrelse | Opioidafhængighed | Opioidbrug | Opioidmisbrug | Misbrug af opioidForenede Stater